BioStock: Altium fuels PHI’s forward drive
PHI’s largest investor, Altium S.A., has intensified its support for the company with a directed share issue of 9.9 MSEK, subject to approval at an extraordinary shareholder meeting. This investment extends PHI’s financial runway beyond 2025 and accelerates its GMP and regenerative medicine projects.
BioStock connects with Goran Dubravčić, Altium’s CEO and PHI’s newly appointed Chairman of the Board, to explore these pivotal developments and their impact on PHI’s trajectory.
Read the full interview with Goran Dubravčić on biostock.se.